Cargando…

Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis

Axonal loss is the main cause of irreversible disability in multiple sclerosis (MS). Serum neurofilament light (sNfL) is a biomarker of axonal disintegration. In this nested case–control study, blood samples from 519 presymptomatic persons (age range 4–39 years) who later received an MS diagnosis sh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jons, Daniel, Zetterberg, Henrik, Biström, Martin, Alonso‐Magdalena, Lucia, Gunnarsson, Martin, Vrethem, Magnus, Blennow, Kaj, Nilsson, Staffan, Sundström, Peter, Andersen, Oluf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186135/ https://www.ncbi.nlm.nih.gov/pubmed/35502756 http://dx.doi.org/10.1002/acn3.51568

Ejemplares similares

High serum concentration of vitamin D may protect against multiple sclerosis
por: Biström, Martin, et al.
Publicado: (2019)

Systemic inflammation and risk of multiple sclerosis – A presymptomatic case-control study
por: Grut, Viktor, et al.
Publicado: (2022)

Free vitamin D(3) index and vitamin D‐binding protein in multiple sclerosis: A presymptomatic case–control study
por: Grut, Viktor, et al.
Publicado: (2022)

Epstein–Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosis
por: Biström, M., et al.
Publicado: (2020)

Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis
por: Håkansson, Irene, et al.
Publicado: (2018)

Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus
por: Tyrberg, Tobias, et al.
Publicado: (2020)

Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study
por: Eckerström, Marie, et al.
Publicado: (2020)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage
por: Tobieson, Lovisa, et al.
Publicado: (2021)

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
por: Novakova, Lenka, et al.
Publicado: (2017)

The effect of vitamin B supplementation on neuronal injury in people living with HIV: a randomized controlled trial
por: Tyrberg, Erika, et al.
Publicado: (2022)

Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection
por: Hermansson, Linn, et al.
Publicado: (2019)

Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease
por: Voevodskaya, Olga, et al.
Publicado: (2016)

Slowing gait speed precedes cognitive decline by several years
por: Skillbäck, Tobias, et al.
Publicado: (2022)

Biomarker Evidence of Axonal Injury in Neuroasymptomatic HIV-1 Patients
por: Jessen Krut, Jan, et al.
Publicado: (2014)

Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?
por: Bloniecki, Victor, et al.
Publicado: (2020)

Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection
por: Bremell, Daniel, et al.
Publicado: (2013)

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
por: Gisslén, Magnus, et al.
Publicado: (2015)

Corrigendum to: “Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study” [EBioMedicine 3 (216) 135–140]
por: Gisslén, Magnus, et al.
Publicado: (2016)

Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
por: Bergman, Joakim, et al.
Publicado: (2016)

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate
por: Hermansson, Linn, et al.
Publicado: (2019)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds
por: Remnestål, Julia, et al.
Publicado: (2021)

Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up
por: Kanberg, Nelly, et al.
Publicado: (2021)

Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample
por: Arvidsson Rådestig, Maya, et al.
Publicado: (2023)

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
por: Johnsson, Magnus, et al.
Publicado: (2022)

A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease
por: Andersson, Carl-Henrik, et al.
Publicado: (2016)

VALZ‐Pilot: High‐dose valacyclovir treatment in patients with early‐stage Alzheimer's disease
por: Weidung, Bodil, et al.
Publicado: (2022)

Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App(NL−F/NL−F) knock-in mouse model of Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2023)

Association of the RAGE G82S polymorphism with Alzheimer’s disease
por: Daborg, Jonny, et al.
Publicado: (2010)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010)

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders
por: Andreasson, Ulf, et al.
Publicado: (2016)

Repeated lumbar punctures within 3 days may affect CSF biomarker levels
por: Olsson, Martin, et al.
Publicado: (2019)

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2020)

Axonal Dysfunction Precedes Motor Neuronal Death in Amyotrophic Lateral Sclerosis
por: Iwai, Yuta, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vrhckjvpettf0p6hg1409i85p5